Alnylam Pharmaceuticals reported $42.61M in Interest Expense on Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US $ 42.61M 247K
Amgen AMGN:US $ 328M 33M
Biocryst Pharmaceuticals BCRX:US $ 24.02M 0.18M
Biomarin Pharmaceutical BMRN:US $ 3.86M 0.05M
Intercept Pharmaceuticals ICPT:US $ 6.67M 0M
Moderna Inc MRNA:US 5M 1000K
Neurocrine Biosciences NBIX:US $ 2.2M 0.4M
Novartis NVS:US $ 202M 1M
Ptc Therapeutics PTCT:US $ 22.28M 1.34M
Regeneron Pharmaceuticals REGN:US $ 13.1M 0.5M
Regulus Therapeutics RGLS:US $ 0.16M 0.01M
Sarepta Therapeutics SRPT:US $ 16.03M 0.23M
Vertex Pharmaceuticals VRTX:US $ 14.6M 0.3M
YTE INCY:US $ 0.68M 0M